Novo Nordisk's semaglutide shows improved mental and physical wellbeing as obesity treatment

New data suggests that Novo Nordisk's molecule semaglutide improves the mental and physical wellbeing of obesity patients according to results from the pharmaceutical company's Step program.


A weekly dose of Novo Nordisk's semaglutide as a treatment for obesity seems to result in weight loss as well as improved physical function and psychological wellbeing, according to results from the Danish pharmaceutical firm's phase IIIa known as Step 1.

The data was introduced on Thursday in connection with the annual conference for the European Congress on Obesity (ECO).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs